neurology

News

Lundbeck preps phase 3 for migraine prevention drug

Lundbeck seems to have brought its migraine prevention drug bocunebart back on track with positive data for an intravenous formulation.

News

Data builds on Roche's dominance in primary progressive MS

Roche looks on track to add oral BTK inhibitor fenebrutinib to treatment options for primary progressive multiple sclerosis.

News

Bayer reveals data behind asundexian's stroke win

Bayer's oral Factor XIa inhibitor asundexian can reduce the risk of a secondary ischaemic stroke by 26%, according to the OCEANIC-STROKE trial.

R&D

Organoid neurotoxicity testing gains momentum

Organoid-based approaches may become an integral part of neurological safety testing, offering a clearer view of risk.

Digital

pharmaphorum podcast Episode 236, Tarek Samad, Lundbeck

An AI supercomputer and discovering next-gen brain disorder ...

Tarek Samad, Lundbeck’s senior vice president and head of research, discusses AI – specifically, Lundbeck’s agreement with the DCAI to operate Gefion.

R&D

Q4 Clinical trials round-up: October to December 2025

We round up the key data and innovations in Q4 2025 - and what these likely presage for 2026’s R&D focus.

Lundbeck preps phase 3 for migraine prevention drug

Data builds on Roche's dominance in primary progressive MS

Bayer reveals data behind asundexian's stroke win

Organoid neurotoxicity testing gains momentum

An AI supercomputer and discovering next-gen brain disorder ...

Q4 Clinical trials round-up: October to December 2025

NHS "isn't delivering equitable care for rare diseases"

Using AI-driven synthetic personas to take your insights fur...

neurology

Editor's Picks